Edgewise Therapeutics Inc
EWTXHealthcare|Biotechnology|USA
$45.41
-2.94 (-6.08%)
Tangible Book
$4.59
Earnings Power
$4.34
Upcoming Data Readouts (4)
Aug 2026
Est. completion
Sep 2026
Est. completion
P2Becker Muscular Dystrophy
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
NCT05291091n=244
Jan 2027
Est. completion
P2Duchenne Muscular Dystrophy
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
NCT05540860n=76
Mar 2027
Est. completion
P2Duchenne Muscular Dystrophy
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
NCT06100887n=43
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.